OncoVista Innovative Valuation
| OVIT Stock | USD 0.0001 0.00 0.00% |
OncoVista Innovative seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of OncoVista Innovative from analyzing the company fundamentals such as Net Income of (2.54 M), return on asset of -23.58, and Price To Earning of (0.12) X as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that OncoVista Innovative's price fluctuation is very steady at this time. Calculation of the real value of OncoVista Innovative is based on 3 months time horizon. Increasing OncoVista Innovative's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
OncoVista Innovative's intrinsic value may or may not be the same as its current market price of 0.0001, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 |
The intrinsic value of OncoVista Innovative's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence OncoVista Innovative's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of OncoVista Innovative Therapies helps investors to forecast how OncoVista pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of OncoVista Innovative more accurately as focusing exclusively on OncoVista Innovative's fundamentals will not take into account other important factors: OncoVista Innovative Total Value Analysis
OncoVista Innovative Therapies is now forecasted to have valuation of 852.92 K with market capitalization of 558.34 K, debt of 479.3 K, and cash on hands of 61.27 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the OncoVista Innovative fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
852.92 K | 558.34 K | 479.3 K | 61.27 K |
OncoVista Innovative Asset Utilization
One of the ways to look at asset utilization of OncoVista is to check how much profit was generated for every dollar of assets it reports. OncoVista Innovative holds a negative application of assets of -23.58 pct., losing $0.24 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of OncoVista Innovative Therapies shows how discouraging it operates for each dollar spent on its assets.OncoVista Innovative Profitability Analysis
Net Loss for the year was (2.54 M) with profit before overhead, payroll, taxes, and interest of 0.About OncoVista Innovative Valuation
The pink sheet valuation mechanism determines OncoVista Innovative's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of OncoVista Innovative based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of OncoVista Innovative. We calculate exposure to OncoVista Innovative's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of OncoVista Innovative's related companies.OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company was founded in 2004 and is based in San Antonio, Texas. ONCOVISTA INNOVATIVE operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
8 Steps to conduct OncoVista Innovative's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates OncoVista Innovative's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct OncoVista Innovative's valuation analysis, follow these 8 steps:- Gather financial information: Obtain OncoVista Innovative's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine OncoVista Innovative's revenue streams: Identify OncoVista Innovative's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research OncoVista Innovative's industry and market trends, including the size of the market, growth rate, and competition.
- Establish OncoVista Innovative's growth potential: Evaluate OncoVista Innovative's management, business model, and growth potential.
- Determine OncoVista Innovative's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate OncoVista Innovative's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
OncoVista Innovative Growth Indicators
Investing in growth stocks can be very risky. If the company such as OncoVista Innovative does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Retained Earnings | -25.9 M |
Additional Tools for OncoVista Pink Sheet Analysis
When running OncoVista Innovative's price analysis, check to measure OncoVista Innovative's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoVista Innovative is operating at the current time. Most of OncoVista Innovative's value examination focuses on studying past and present price action to predict the probability of OncoVista Innovative's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoVista Innovative's price. Additionally, you may evaluate how the addition of OncoVista Innovative to your portfolios can decrease your overall portfolio volatility.